Alembic Global Advisors is an independent equity research firm offering differentiated, experienced financial analysis on a variety of global industrial sectors. Our goal is to provide high quality, proprietary and actionable research into company, industry and broader macro trends on a truly global level.
Since its founding in 2009, Alembic has expanded from its core global chemical coverage to the aerospace & defense sector. Our analysts have been recognized by industry publications Institutional Investor, FT/Starmine and Extel.2 research analysts covering 35 companies across 3 industries (Chemicals and Aerospace & Defense). Our coverage list continues to grow as we remain focused on delivering our best-in-class research product.
Through our corporate access events we provide unique opportunities to meet with a select group of industry leaders, offering the chance to gain unique insights from people operating at the highest levels of their respective industries.
In addition to highly analytical deep dive research surrounding our specific equity coverage, we provide our macro view of each industry against the global backdrop of current events and how we see them shaping the future. We leverage our various areas of expertise to produce a collaborative cross-sector research product. This non-siloed approach allows us to maximize our areas of expertise, ultimately achieving a more dynamic and in-depth level of insight.
Not a client? Please contact Stephen Matthews – stephen.matthews@alembicglobal.com – to learn more about our research subscription offerings.
Access is limited to Alembic Global Advisors clients.
Key Points CE is ~75% off peak and below COVID lows—priced for balance-sheet distress Debt fear fading. Refinancings, USD2 quarterly EPS path, FCF, and asset sales cover maturities We rate ......
Key Points We expect Q4’25 EPS to come in ~28% below consensus on average 2026 estimates moving lower as recovery pushed out For 2026, Overweight-rated SABIC is our top pick, ......
Key Points We’re raising our rating on shares of NOC to Overweight and increasing our target price by USD26 to USD662. This is the first time we’ve updated our forecast ......
Key Points Beatable setup: Destocking is largely done, U.S. cost advantage intact, and 2026 consensus embeds no recovery—leaving clear upside to estimates Tightening tailwinds: Anti-dumping actions and accelerating global capacity ......